Idiopathic Pulmonary Fibrosis

September 3, 2015November 5, 2015

September is PFF’s Global Pulmonary Fibrosis Awareness Month

The Pulmonary Fibrosis Foundation (PFF) kicks off its Global Pulmonary Fibrosis Awareness Month this September 2015, with a mission to better educate the public on the chronic and crippling disease, and at ... Read more

August 31, 2015November 5, 2015

Pulmonary Fibrosis Foundation & Veracyte Partner To Advance Interstitial Lung Disease Survey

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) and Veracyte, Inc have recently announced they are partnering on a survey for United States patients in order to develop better insights concerning patients’ diagnostic experiences with interstitial lung diseases ... Read more

August 26, 2015November 5, 2015

Researchers Determine the Influence of the Vagus Nerve in Pulmonary Fibrosis Due to Bleomycin

Idiopathic Pulmonary Fibrosis, News

A newly published paper in the Scientific Reports journal entitled “Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice” suggests that activation of the pair of nerves emerging from the brain that control the heart and digestive ... Read more

August 13, 2015November 5, 2015

Sanofi’s Phase 2 Clinical Trial on SAR156597 for Idiopathic Pulmonary Fibrosis Treatment Currently Recruiting Participants

Idiopathic Pulmonary Fibrosis, News

Sanofi is currently recruiting participants to enroll in a phase 2 clinical trial designed to assess the safety and efficacy of its product SAR156597 in the treatment of idiopathic pulmonary ... Read more

August 13, 2015November 5, 2015

American Thoracic Society Recommends Esbriet (Pirfenidone) in Updated IPF Treatment Guidelines

Idiopathic Pulmonary Fibrosis, News

Esbriet (pirfenidone) by Genentech was recently included in the American Thoracic Society’s (ATS) updated idiopathic pulmonary fibrosis (IPF) treatment guidelines, which presents the drug’s proven benefits in delaying disease progression, as determined ... Read more

August 10, 2015November 5, 2015

Pharmaxis And Synairgen Collaborate To Advance LOXL2 Inhibitor For Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

Australian pharmaceutical company Pharmaxis Ltd and UK based Synairgen plc have signed a research partnership to advance a selective inhibitor for the LOXL2-lysyl oxidase type 2 enzyme in order to treat idiopathic pulmonary fibrosis (IPF), a fatal ... Read more

August 6, 2015November 5, 2015

Collaboration Between Pharmaxis and Synairgen in LOXL2 Inhibitor Development for IPF

Idiopathic Pulmonary Fibrosis, News

Pharmaxis Ltd and Synairgen plc recently announced a collaboration with the goal of developing a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) as a therapy for idiopathic pulmonary ... Read more

August 3, 2015November 5, 2015

Roche’s Pirfenidone (Esbriet) Found to Offer Therapeutic Benefit For IPF in a Clinical Practice Setting

Idiopathic Pulmonary Fibrosis, News

A new study recently published in the journal Advances in Therapy provided evidence of the therapeutic benefit of pirfenidone (known by the brand name Esbriet) for IPF patients in a ... Read more

July 30, 2015November 5, 2015

Moerae Initiates Second Phase 1 study of MMI-0100 for Lung Diseases

Idiopathic Pulmonary Fibrosis, News

Moerae Matrix Inc., a privately held biopharmaceutical company focused on the development of first-in-class targeted therapeutics for fibrotic diseases, recently announced the initiation of its second Phase 1 clinical trial ... Read more

July 28, 2015November 5, 2015

Researchers Find Increased Protein Turnover Linked to the Development of IPF

Idiopathic Pulmonary Fibrosis, News

In a recent study published in the American Journal of Respiratory and Critical Care Medicine, a team of researchers from the Helmholtz Zentrum München was able to identify a novel ... Read more